Heparinas de bajo peso molecular en pacientes con enfermedad renal crónica ¿Es seguro su uso?

• JORGE VEGA S ^[1] ; GONZALO MARTÍNEZ R ^[1] ; HELMUTH GOECKE S ^[1]
  1. [1] Hospital Naval Almirante Nef

     Hospital Naval Almirante Nef

     Viña del Mar, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 138, Nº. 4, 2010, págs. 487-495
• Idioma: español
• Títulos paralelos:
  • Are low-molecular-weight heparins safe in patients with chronic kidney disease?
• Enlaces
  • Texto completo
• Resumen

  • Due to their effcacy and convenience, low-molecular-weight heparins (LMWH) are used as sustitutes of unfractionated heparin. Unfortunately, most of the evidence about safety and usefulness of LMWH have excluded patients with chronic kidney disease (CKD), in whom their elimination clearance is reduced, allowing an increased anticoagulant effect. Accordingly, there is a growing number of reports about major and fatal bleeding episodes in this group of patients using LMWH. At the present stage of knowledge, there is no defnitive cut-off value of renal function to adjust the doses or avoid the administration of LMWH, making their effects unpredictable in patients with CKD. Hence, it is reasonable to avoid the use of these drugs in patients with CKD, while awaiting for more evidence that supports their safer use.